Trial Profile

A phase III study in mazindol in patients with attention deficit hyperactivity disorder

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mazindol (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Registrational; Therapeutic Use
Sponsors NLS Pharma Ltd; NLS Pharmaceutics Ltd

Most Recent Events

27 Feb 2019 According to a NLS-I pharma media release, this drug is expected to reach the U.S. market as early as 2022, pending regulatory approval and other factors.
27 Feb 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com